Tazemetostat hydrobromide
氢溴酸他泽司他EZH2 inhibitor listed in the 2025 Commercial List (#16) for EZH2-mutated r/r follicular lymphoma; not carried into the 2026 Commercial List or 2026 NRDL.
China Approval (NMPA)
Pending VerificationReimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.
National Reimbursement
Not ListedNot included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).
Commercial Insurance List
2025 Only (Not in 2026)Previously listed in the 2025 Commercial Insurance Innovative Drug List (#16). Omitted from the 2026 Commercial List edition.
Approved Products, Dosage Forms & Approval Numbers
0 verified NMPA recordsChange Timeline
- (2026-01-01)Commercial List· Catalog published: Dec 7, 2025
2025 Commercial List · Removed in 2026 Edition (#16)
Monotherapy for adult EZH2-mutation-positive r/r follicular lymphoma after ≥2 prior systemic therapies (listed in 2025 Commercial List #16; omitted from 2026 edition).
Chinese original: 单药用于既往接受过至少两种系统性治疗后的EZH2突变阳性复发或难治性滤泡性淋巴瘤(FL)成人患者。
NHSA · PDF p.4Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2025-12-07商业健康保险创新药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20